For over a decade, Fed forward guidance and QE have suppressed interest rate volatility. A shift away from this communication strategy would likely cause volatility to return to the more "normal," higher levels seen before the 2008 global financial crisis.

A key risk for 2026 is the disconnect between stretched market valuations (e.g., tight credit spreads in the 1st percentile) and a macroeconomic environment that doesn't feel late-cycle. This tension suggests that even if growth drives equities higher, it could be accompanied by increased volatility or widening credit spreads.

Middle East conflicts can spike oil prices and inflation, leading to higher interest rates. This disproportionately hurts smaller, cash-burning biotechs that rely on accessible capital, making them more vulnerable than larger firms during periods of global uncertainty.

The common assumption is that reduced Fed forward guidance increases uncertainty, leading to a higher term premium and bond yields. However, this creates volatility in both directions. While yields might rise in an inflationary environment, a lack of guidance could also cause them to fall sharply during a period of negative economic surprises.

While investors often watch equity markets for signs of Fed intervention, rising bond volatility poses a more significant risk to financial conditions. This makes the Fed more sensitive to instability in the bond market, meaning a spike there could trigger a dovish policy shift sooner than a stock market downturn.

The bond market will become volatile not when rates hit a certain number, but when the market perceives the Fed's cutting cycle has ended and the next move could be a hike. This "legitimate pause" will cause a rapid, painful steepening of the yield curve.

The long-dated nature of biotech investing makes it uniquely vulnerable to high interest rates. A 5% rate applied over a 10-15 year development cycle can compress valuation multiples by three to fourfold, drastically changing the financial landscape for the industry.

The macro trend of rising bond yields creates a specific, acute risk for the AI sector. Many AI startups are funded by floating-rate private credit, and their debt service costs will explode as rates rise. This is compounded by high CapEx and an inability to scale revenues proportionally, creating a potential crash.

Once considered safe due to low CapEx and recurring revenue models, the technology sector now shows significant credit stress. Investors allowed higher leverage on these companies, but the sharp rise in interest rates in 2022 exposed this vulnerability, placing tech alongside historically troubled sectors like media and retail.